- Home
- GENC vs PVLA Comparison
GENC vs PVLA Comparison
Compare GENC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENC
- PVLA
- Stock Information
- Founded
- GENC 1894
- PVLA 2015
- Country
- GENC United States
- PVLA United States
- Employees
- GENC N/A
- PVLA N/A
- Industry
- GENC Construction/Ag Equipment/Trucks
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- GENC Industrials
- PVLA Health Care
- Exchange
- GENC Nasdaq
- PVLA Nasdaq
- Market Cap
- GENC 215.0M
- PVLA 249.2M
- IPO Year
- GENC N/A
- PVLA N/A
- Fundamental
- Price
- GENC $14.85
- PVLA $27.52
- Analyst Decision
- GENC
- PVLA Strong Buy
- Analyst Count
- GENC 0
- PVLA 7
- Target Price
- GENC N/A
- PVLA $46.29
- AVG Volume (30 Days)
- GENC 27.7K
- PVLA 128.9K
- Earning Date
- GENC 08-08-2025
- PVLA 08-15-2025
- Dividend Yield
- GENC N/A
- PVLA N/A
- EPS Growth
- GENC N/A
- PVLA N/A
- EPS
- GENC 0.99
- PVLA N/A
- Revenue
- GENC $113,166,000.00
- PVLA N/A
- Revenue This Year
- GENC N/A
- PVLA N/A
- Revenue Next Year
- GENC N/A
- PVLA N/A
- P/E Ratio
- GENC $15.34
- PVLA N/A
- Revenue Growth
- GENC 7.70
- PVLA N/A
- 52 Week Low
- GENC $10.80
- PVLA $11.17
- 52 Week High
- GENC $24.88
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- GENC 58.08
- PVLA N/A
- Support Level
- GENC $14.72
- PVLA N/A
- Resistance Level
- GENC $15.47
- PVLA N/A
- Average True Range (ATR)
- GENC 0.66
- PVLA 0.00
- MACD
- GENC 0.02
- PVLA 0.00
- Stochastic Oscillator
- GENC 85.03
- PVLA 0.00
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.